Global Information
회사소개 | 문의 | 비교리스트

세계의 비알코올성 지방간염(NASH) 치료제 시장 : COVID-19의 잠재적 영향에 관한 인사이트와 예측(2020-2029년)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)

리서치사 Koncept Analytics
발행일 2020년 07월 상품 코드 948344
페이지 정보 영문 102 Pages
가격
US $ 1,700 ₩ 2,036,000 PDF (Single User License)
US $ 2,300 ₩ 2,755,000 PDF (Corporate User License)


세계의 비알코올성 지방간염(NASH) 치료제 시장 : COVID-19의 잠재적 영향에 관한 인사이트와 예측(2020-2029년) Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)
발행일 : 2020년 07월 페이지 정보 : 영문 102 Pages

세계의 비알코올성 지방간염(NASH) 치료제 시장은 2029년에 843억 4,000만 달러를 기록했습니다. 이 시장은 2018-2029년의 예측 기간에 39.13%의 CAGR로 성장할 전망입니다. 헬스케어비의 증가, 의약품 연구개발비의 증가, 당뇨병 인구의 급증, 비만 인구의 증가, 잠재적 요구, 좌식 생활방식 등의 요인이 이 시장의 성장을 촉진할 것으로 예상되고 있습니다. 그러나 활발하지 못한 치료제 승인 프로세스, 높은 치료비, NASH/NAFLD의 적은 확정적 진단 방법 등은 이 시장의 과제입니다. 시장의 주목 해야 할 동향으로는 NASH 주요 의약품의 급증하는 시장 침투, NASH의 유병률 증가, NASH 진단 방법과 바이오마커의 진보, 개발중인 NASH 파이프라인 의약품 및 E-Commerce 의약품 판매의 증가 등을 들 수 있습니다.

세계의 비알코올성 지방간염(NASH) 치료제 시장에 대해 조사했으며, 시장 성장요인 및 과제, 동향 및 개발, COVID-19의 영향, 약제 유형·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 시장 개요

  • 서론
  • 원인과 증상
  • 진단
  • 처리
  • 적응외 치료
  • 치료상 시술

제2장 COVID-19의 영향

  • COVID-19 증례 수의 증가
  • 정부에 의한 헬스케어비의 증가
  • 바이오마커 용도의 증가
  • NASH 치료제 임상시험에 대한 영향

제3장 세계 시장

  • 시장 예측 : 가치별
  • 가치(예측) : 약제 클래스별
  • 적응외 의약품 : 가치별

제4장 세계의 치료제 시장

  • 가치별 예측
  • 약제 유형별 시장 가치 예측
    • 2024년 예측
    • 2029년 예측
    • Obeticholic Acid(OCA) : 가치별
    • Obeticholic Acid(OCA) : 지역별
    • Cenicriviroc(CVC) : 가치별
    • Cenicriviroc(CVC) : 지역별
    • Elafibranor : 가치별
    • Aramchol : 가치별
    • MGL-3196 : 가치별
    • INN-217 : 가치별
    • VK2809 : 가치별
  • 지역별 시장 가치 예측
    • 2024년 예측
    • 2029년 예측

제5장 시장 예측 : 지역별

  • 미국
  • 유럽
  • 기타 지역

제6장 시장 역학

  • 성장요인
    • 상승하는 헬스케어 지출
    • 의약품 연구개발비의 증가
    • 급증하는 당뇨병 인구
    • 비만 인구의 증가
    • 미충족 의료 요구
    • 좌식 생활방식
  • 주요 동향과 개발
    • 주요 NASH약의 급증하는 시장 침투
    • NASH의 유병률 증가
    • 진행중인 NASH 진단 방법과 바이오마커
    • 개발중인 NASH 파이프라인 의약품
    • E-Commerce 의약품 판매량의 성장
  • 과제
    • 활발하지 못한 약물 승인 프로세스
    • 높은 치료비
    • 관련 비지니스 리스크
    • NASH/NAFLD의 비결정적인 진단 방법

제7장 경쟁 구도

  • 세계 시장
    • 주요 기업 : 매출 비교
    • 주요 기업 : 시가총액 비교
    • 주요 기업 : R&D 비교
    • 주요 기업 : 제품 포트폴리오 비교

제8장 기업 개요

  • Bristol Myers Squibb
  • Gilead Sciences, Inc.
  • Allergan(Abbvie)
  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals
  • Genfit SA
KSA 20.07.29

List of Figures

  • NAFLD Spectrum and Estimated Advancement Risk
  • Treatment of NASH
  • Potential Phase III NASH Drugs
  • Global Government Share on Health Spending (2019-2024)
  • Global Biomarkers Market Value Forecast (2016-2021)
  • Global NASH Drugs Market Forecast by Value (2018-2029)
  • Global NASH Drugs Market Value Forecast by Drug Class (2019/2024/2029)
  • Global NASH Off-Label Drugs Market Forecast by Value (2018-2029)
  • Global NASH Therapeutics Market Forecast by Value (2020-2029)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
  • Global Obeticholic Acid (OCA) Drug Market Forecast by Value (2020-2029)
  • Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region (2029)
  • Global Cenicriviroc (CVC) Drug Market Forecast by Value (2020-2029)
  • Global Cenicriviroc (CVC) Drug Market Value Forecast by Region (2029)
  • Global Elafibranor Drug Market Forecast by Value (2020-2029)
  • Global Aramchol Drug Market Forecast by Value (2022-2029)
  • Global MGL-3196 Drug Market Forecast by Value (2023-2029)
  • Global INN-217 Drug Market Forecast by Value (2023-2029)
  • Global VK2809 Drug Market Forecast by Value (2023-2029)
  • Global NASH Therapeutics Market Value Forecast by Region (2024)
  • Global NASH Therapeutics Market Value Forecast by Region (2029)
  • The U.S. NASH Therapeutics Market Forecast by Value (2022-2029)
  • Europe NASH Therapeutics Market Forecast by Value (2022-2029)
  • ROW NASH Therapeutics Market Forecast by Value (2022-2029)
  • Global HealthCare Expenditure Per Capita (2014-2019)
  • Global Pharmaceutical R&D Expenditures (2014-2019)
  • Global Prevalence of Diabetes (2014-2019)
  • Global Obese Patient Population (2014-2019)
  • Number of NASH Patients treated with Ocaliva and Selonsertib Forecast (2020-2025)
  • The US NASH Patient Population (2018-2028)
  • Global E-Commerce Pharmaceutical Products Sales (2018-2023)
  • Drugs Approval Process
  • Bristol Myers Squibb Total Revenue and Net Earnings (2015-2019)
  • Bristol Myers Squibb Revenue by Segment (2019)
  • Bristol Myers Squibb Revenue by Region (2019)
  • Gilead Sciences Revenue and Net Income (2015-2019)
  • Gilead Sciences Revenue by Segment (2019)
  • Gilead Sciences Revenue by Region (2019)
  • Allergan Plc. (Abbvie) Net Revenue and Net Loss (2015-2019)
  • Allergan Plc. (Abbvie) Net Revenue by Segment (2019)
  • Intercept Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Intercept Pharmaceuticals Revenue by Segment (2019)
  • Galmed Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Genfit SA Revenue and Net Loss (2015-2019)

List of Tables

  • NASH Off-Label Therapies
  • Total Confirmed COVID-19 Cases Worldwide (2020)
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2019)
  • Drugs under Development for NASH (2019)
  • NASH Annual Treatment Cost Comparison (2019)
  • Key Players - Revenue Comparison (2019)
  • Key Players - Market Cap Comparison (2020)
  • Key Players - R&D Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Intercept Pharmaceuticals Product Pipeline (2019)
  • Genfit SA Product Pipeline (2019)

The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales.

The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:

The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.

The major regional markets (the U.S., Europe and Rest of World) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.

Key Target Audience:

  • NAFLD/NASH Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Causes & Symptoms
  • 1.3. Diagnosis
  • 1.4. Treatment
  • 1.5. Off-Label Treatment
  • 1.6. Therapeutic Treatment

2. Impact of COVID-19

  • 2.1. Rise in Number of COVID-19 Cases
  • 2.2. Growth in Government Spending on Healthcare
  • 2.3. Rise in Application of Biomarkers
  • 2.4. Impact on NASH Therapeutics Clinical Trials

3. Global NASH Market

  • 3.1. Global NASH Drugs Market Forecast by Value
  • 3.2. Global NASH Drugs Market Value Forecast by Drug Class
  • 3.3. Global NASH Off-Label Drugs Market Forecast by Value

4. Global NASH Therapeutics Market

  • 4.1. Global NASH Therapeutics Market Forecast by Value
  • 4.2. Global NASH Therapeutics Market Value Forecast by Drug Type
    • 4.2.1. Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
    • 4.2.2. Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
    • 4.2.3. Global Obeticholic Acid (OCA) Drug Market Forecast by Value
    • 4.2.4. Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region
    • 4.2.5. Global Cenicriviroc (CVC) Drug Market Forecast by Value
    • 4.2.6. Global Cenicriviroc (CVC) Drug Market Value Forecast by Region
    • 4.2.7. Global Elafibranor Drug Market Forecast by Value
    • 4.2.8. Global Aramchol Drug Market Forecast by Value
    • 4.2.9. Global MGL-3196 Drug Market Forecast by Value
    • 4.2.10. Global INN-217 Drug Market Forecast by Value
    • 4.2.11. Global VK2809 Drug Market Forecast by Value
  • 4.3. Global NASH Therapeutics Market Value Forecast by Region
    • 4.3.1. Global NASH Therapeutics Market Value Forecast by Region (2024)
    • 4.3.2. Global NASH Therapeutics Market Value Forecast by Region (2029)

5. Regional NASH Market

  • 5.1. The U.S. NASH Therapeutics Market Forecast by Value
  • 5.2. Europe NASH Therapeutics Market Forecast by Value
  • 5.3. ROW NASH Therapeutics Market Forecast by Value

6. Market Dynamics

  • 6.1. Growth Drivers
    • 6.1.1. Rising HealthCare Expenditure
    • 6.1.2. Increase in Pharmaceutical R&D Expenditures
    • 6.1.3. Surging Diabetic Population
    • 6.1.4. Escalating Obese Population
    • 6.1.5. Unmet Medical Needs
    • 6.1.6. Sedentary Lifestyle
  • 6.2. Key Trends & Development
    • 6.2.1. Surging Market Penetration for Major NASH Drugs
    • 6.2.2. Increasing Prevalence of NASH
    • 6.2.3. Progressing NASH Diagnosis Methods and Biomarkers
    • 6.2.4. NASH Pipeline Drugs Under Development
    • 6.2.5. Growth in E-Commerce Pharmaceutical Products Sales
  • 6.3. Challenges
    • 6.3.1. Lethargic Drug Approval Process
    • 6.3.2. High Treatment Cost
    • 6.3.3. Associated Business Risk
    • 6.3.4. Less Definitive Diagnostic Methods for NASH/NAFLD

7. Competitive Landscape

  • 7.1. Global NASH Drugs Market
    • 7.1.1. Key Players - Revenue Comparison
    • 7.1.2. Key Players - Market Cap Comparison
    • 7.1.3. Key Players - R&D Comparison
    • 7.1.4. Key Players - Product Portfolio Comparison

8. Company Profiles

  • 8.1. Bristol Myers Squibb
    • 8.1.1. Business Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Business Strategies
  • 8.2. Gilead Sciences, Inc.
    • 8.2.1. Business Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Strategies
  • 8.3. Allergan (Abbvie)
    • 8.3.1. Business Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Strategies
  • 8.4. Intercept Pharmaceuticals, Inc.
    • 8.4.1. Business Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Business Strategies
  • 8.5. Galmed Pharmaceuticals
    • 8.5.1. Business Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Business Strategies
  • 8.6. Genfit SA
    • 8.6.1. Business Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Business Strategies
Back to Top
전화 문의
F A Q